The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.
 
Ramona Erber
Honoraria - AstraZeneca/Daiichi Sankyo; Diaceutics; Mindpeak; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo
Research Funding - Biocartis (Inst); Gilead Sciences; Owkin (Inst); Palleos (Inst)
Expert Testimony - Mindpeak
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Exact Sciences; Gilead Sciences; Lilly; MSD Oncology; Novartis; Onkowissen; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Johannes Schumacher
No Relationships to Disclose
 
Michael Braun
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Exact Sciences; Gilead Sciences; Novartis; Pfizer
Speakers' Bureau - Exact Sciences; Novartis
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Eva-Maria Grischke
No Relationships to Disclose
 
Christian Schem
No Relationships to Disclose
 
Michael Patrick Lux
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Endomag; Genomic Health; Grunenthal; Hexal; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche Pharma AG; SamanTree Medical
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Endomag; Genomic Health; Grunenthal; Hexal; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche Pharma AG
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai Germany; Endomag; Endomag; Exact Sciences; Grunenthal; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche Pharma AG
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); German Breast Group (Inst); Grunenthal (Inst); MSD Oncology (Inst); PRAEGNANT Network (Inst); Roche (Inst); SamanTree Medical (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche Pharma AG
Other Relationship - Medac
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Endomag; Pfizer
 
Mustafa Deryal
No Relationships to Disclose
 
Oliver Hoffmann
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Hexal; Lilly O.; MSD; Novartis; Pfizer; RIEMSER; Roche; Seagen
 
Bernhard Heinrich
Consulting or Advisory Role - AstraZeneca; Novartis; Roche; Sanofi
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Bristol-Myers Squibb; Clovis Oncology; Janssen-Cilag; Lilly; Novartis; Roche; Sanofi
 
Georg Kunz
No Relationships to Disclose
 
Kristina Luebbe
No Relationships to Disclose
 
Petra Krabisch
No Relationships to Disclose
 
Arndt Hartmann
Honoraria - Abbvie; AstraZeneca; BMS; Boehringer Ingelheim; Ipsen; Janssen-Cilag; MSD; Roche
Consulting or Advisory Role - 3DHISTECH; AstraZeneca; Bristol-Myers Squibb; Cepheid; Diaceutics; Illumina; Ipsen; Janssen-Cilag; MSD; NanoString Technologies; Qiagen; Roche
Research Funding - AstraZeneca; BioNTech; Cepheid; Janssen-Cilag; NanoString Technologies; Roche
Expert Testimony - NanoString Technologies
 
Philip Raeth
Employment - Palleos
Stock and Other Ownership Interests - Palleos
 
Sabine Kasimir-Bauer
Consulting or Advisory Role - Quiagen
 
Cornelia Kolberg-Liedtke
Employment - Palleos
Leadership - Phaon Scientific
Stock and Other Ownership Interests - Phaon Scientific; Phaon Scientific (I); Theraclion (I)
Honoraria - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Carl Zeiss Meditec (I); Exact Sciences (I); Novartis; Novartis (I); Pfizer; Pfizer (I); Roche; Roche (I)
Consulting or Advisory Role - Agendia (I); Aurikamed; Daiichi Sankyo Europe GmbH (I); Genzyme; Gilead Sciences; Gilead Sciences (I); Lilly (I); MSD; Novartis (I); Onkowissen; Onkowissen (I); Pfizer (I); SeaGen; SeaGen (I)
Research Funding - Gilead Sciences
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca (I); Roche Pharma AG
Other Relationship - Gilead Sciences